HEALIUS LIMITED — M&A Activity 2022

Jan 31, 2022

ASX Announcement (ASX: HLS)

ASX Limited Market Announcements Office Exchange Centre Level 4, 20 Bridge Street Sydney NSW 2000

==> picture [138 x 29] intentionally omitted <==

ACN 064 530 516 REGISTERED OFFICE: LEVEL 6 203 PACIFIC HIGHWAY ST LEONARDS NSW 2065 TEL: +61 2 9432 9400 FAX: +61 2 9432 9447

1 February 2022

Healius announces completion of Agilex Biolabs acquisition

Healius (ASX: HLS) today announces that it has completed the acquisition of all of the issued capital of Agilex, one of Australia’s leading bioanalytical laboratories, for an enterprise value of $301.3 million.

Healius’ Managing Director and CEO, Dr Malcolm Parmenter, said: “We see Agilex as a natural fit into our existing pathology business and a logical entry point to the fast-growing global bioanalytical laboratory services market.

“With all its scientists and staff joining us today, I extend a warm welcome to Agilex as it becomes an integral part of Healius pathology and of our future growth plans.”

ENDS

For further information contact:

Janet Payne Charlene Jaw Group Executive, Corporate Affairs Manager, Corporate Affairs Mobile: +61 409 995 517 Mobile: +61 403 222 810

For over 30 years Healius has been one of Australia’s leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has three businesses, pathology, imaging and day hospitals. Through its unique footprint of centres and its 11,000 employees, Healius provides specialty diagnostic services to consumers and their referring practitioners, as well as enabling independent healthcare professionals to deliver care in its day hospitals.